Mammaglobin-A tissue expression and 5-year survival in breast cancer


Year:

Session type:

Theme:

Liz Baker1,Louise Hall2,Deborah Wilson3,Jim France3,Naomi Whiteoal3,Pud Bhaskar3
1North Tees and Hartlepool NHS Foundation Trust,2Royal Victoria Infirmary,3University Hospital of North Tees

Abstract

Background

Human mammaglobin-A is breast tissue-specific, over-expressed in some breast cancers and associated with less aggressive phenotypes. Whilst several previous studies have determined the association between mammaglobin-A protein expression with tumour pathology, it is not known whether this tissue expression correlates with prognosis / 5-year survival.

Method

Paraffin sections from 181 patients who had undergone breast surgery (benign or breast cancer) between October 2007 and June 2010 were analysed for mammaglobin-A protein expression by immunohistochemistry. Tissue expression was compared with histological and clinical parameters; tumour grade, type, size and receptor status (where available). Five year survival analysis was performed (Kaplan Meier, p<0.05). The study had ethics approval.

Results

Positive mammaglobin-A expression was observed in 51% tissue samples. There were no significant associations between mammaglobin-A expression with the breast tumour histological grade, receptor status or size. For histological grade, positive mammaglobin-A expression was observed in 68% benign tissue samples, 55% grade 1, 51% grade 2 and 43% grade 3 tumour tissue samples.

The overall 5-year survival rate was 94%; 10 patients had died, 5 patients were alive with recurrence and 3 were lost to follow-up. There were no significant correlations between tissue mammaglobin-A expression with either overall or disease-free 5-year survival.

Conclusion

A higher proportion of benign and low grade breast tumours demonstrated positive mammaglobin-A tissue expression, however this difference was not significant. In this study positive mammaglobin-A expression was not associated with either disease-free of overall 5-year survival in breast cancer.